Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03095-w
Abstract: Emicizumab reduces bleeding in patients with hemophilia A and inhibitors (PwHA-I). Coagulation potential during the perioperative period in emicizumab-treated PwHA-I undergoing surgery remains to be evaluated. We describe a 14-year-old boy with HA-I receiving emicizumab… read more here.
Keywords: perioperative hemostatic; emicizumab prophylaxis; clot waveform; receiving emicizumab ... See more keywords
Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature
Sign Up to like & getrecommendations! Published in 2021 at "Haemophilia"
DOI: 10.1111/hae.14459
Abstract: Treatment of patients with Haemophilia A has improved significantly in recent years since the advent of novel therapeutic agents such as emicizumab. The low annualised bleeding rates associated with emicizumab have liberated many patients from… read more here.
Keywords: emicizumab prophylaxis; receiving emicizumab; removal; removal patients ... See more keywords
TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
Sign Up to like & getrecommendations! Published in 2025 at "Haemophilia"
DOI: 10.1111/hae.70070
Abstract: Emicizumab is approved for routine prophylaxis, but limited data exist investigating the relationship between bleeds and exercise in people with haemophilia A (PwHA) receiving emicizumab. read more here.
Keywords: tsubasa study; evaluating association; people haemophilia; receiving emicizumab ... See more keywords
Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200784
Abstract: Introduction: The safety and effectiveness of emicizumab, a bispecific factor IXa- and factor X-directed antibody approved for routine prophylaxis in adult and pediatric people with hemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors,… read more here.
Keywords: survey; real world; receiving emicizumab; pwha ... See more keywords